Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

of LX1031 has progressed with the goal of achieving a lower and less frequent dosing regimen that will provide a similar safety and efficacy profile to that observed with the original formulation.  In addition, LX1033, a back-up compound that is approximately 10-fold more potent than LX1031, has completed IND-enabling studies.  It is anticipated that LX1033 will commence Phase 1 testing in the first quarter of 2011.
  • Rheumatoid Arthritis:  Lexicon completed dosing in the expanded Phase 2a clinical trial of its drug candidate for rheumatoid arthritis, LX2931, an inhibitor of sphingosine-1-phosphate lyase.  Top-line data from the study, which enrolled 208 patients and was conducted at multiple centers in the United States and Eastern Europe, are expected to be available by the end of the year.
  • Carcinoid Syndrome:  Enrollment in both the United States and Europe is continuing in the Phase 2a trials for LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels. Preliminary data from both trials are expected to be available in the first half of 2011.

  • Financial Results and EventsOn July 30, 2010, Lexicon exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.  Pursuant to the amended terms of the purchase option, Lexicon paid Symphony Icon Holdings LLC $10 million and agr
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    3. Lexicon to Present at Two Major Healthcare Investor Conferences
    4. Lexicon Announces Pricing of Common Stock in Public Offering
    5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
    6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... BETHESDA, Md. , May 1, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... on the $28.5 million second tranche of a $40 ... ("Woodford"). Woodford first invested $25 million in ... 2015, Woodford entered into an agreement with the Company ...
    (Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North ... it is the proud recipient of two Cisco® Partner Summit ... Partner of the Year and Security Partner of the Year ... conference taking place this week in Montreal ... one, but two Cisco partner awards at this year,s conference," ...
    (Date:5/1/2015)... 2015 According to a ... (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by Technology ... Institutes) - Analysis & Global Forecast to 2019", ... Antibody Production Market for the forecast period of ... reach $2.572 Billion by 2019 from $1.425 Billion ...
    (Date:4/30/2015)... SAN DIEGO , April 30, 2015   ... drugs, announced today an update on its Ebola antiviral ... of Tamir,s leading candidates, TMR004, is currently being evaluated ... frontline of the battle against Ebola. During the first ... Voice And Leadership Meeting To Accelerate The Evaluation of ...
    Breaking Biology Technology:NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
    ... world,s largest library of Jatropha genetic materialSAN DIEGO, Feb. ... of energy, biotechnology and agribusiness veterans today announced the ... CA-based plant oil company specializing in the development of ... Kirk Haney , President and Chief Executive Officer, introduced ...
    ... Feb. 2 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), ... medicine, today announced that it has completed enrolment ... repair device, BST-CarGel(R). The Company achieved its planned ... trial. , "We are grateful to the distinguished ...
    ... HOLLYWOOD, Calif., Feb. 2 IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician ... held in New York, NY. , , ... Speakers: Adam Singer, ... ...
    Cached Biology Technology:Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil 2BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device 2BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device 3IPC The Hospitalist Company, Inc. to Present at UBS 2009 Global Healthcare Services Conference 2
    (Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
    (Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
    (Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
    Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
    ... Family Research and Education Center was awarded a $330,124 grant ... learn through their own creative play in natural playgrounds. The ... will support researchers as they observe young children exploring the ... Nature Center as well as the PlayScape that is currently ...
    ... serious health risks associated with the diets of indigenous ... primary food source to a decrease in the power ... Publishing,s journal Environmental Research Letters , the study ... contaminants, such as mercury, in the subsistence diets that ...
    ... visible light after being exposed to sunlight are commonplace and ... stickers. But until now, scientists have had little success creating ... of the spectrum that only can be seen with the ... in the early online edition of the journal Nature ...
    Cached Biology News:UC Arlitt Center awarded NSF grant to research learning at PlayScapes 2Huskies lend insight into mercury risk 2UGA scientists invent long-lasting, near infrared-emitting material 2
    ... g of monoclonal antibody reactive against the complex ... are highest in growing cultured cells. SURF1 is ... which is thought to participate in the folding ... this subunit. Mutations of SURF1, particularly ones that ...
    Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
    Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
    Tropomyosin 4 [Tm4]...
    Biology Products: